Martin J Connor1, Ailbe Smith2, Saiful Miah3, Taimur T Shah4, Mathias Winkler4, Vincent Khoo5, Hashim U Ahmed4. 1. Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. Electronic address: m.connor@imperial.ac.uk. 2. Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK. 3. Department of Urology, Addenbrooke's Hospital, Cambridge, UK. 4. Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. 5. Department of Clinical Oncology, The Royal Marsden Hospital & Institute of Cancer Research, London, UK.
Abstract
CONTEXT: Metastasis-directed therapy (MDT) in the form of stereotactic ablative radiation therapy (SABR), or in combination with surgical metastasectomy, may have a role in cancer control and disease progression. OBJECTIVE: To perform a systematic review of MDT (surgery or SABR) for oligometastatic (up to 10 metastases, recurrent or de novo) hormone-sensitive prostate cancer in addition to or following primary prostate gland treatment. EVIDENCE ACQUISITION: Medline, Embase, Cochrane Review Database, and clinical trial Databases were systematically searched for clinical trials reporting oncological outcomes and safety. The risk of bias was assessed with the Cochrane 2.0 or ROBINS-I tool. EVIDENCE SYNTHESIS: From 1025 articles identified, four clinical trials met the prespecified criteria. These included two randomised and two nonrandomised clinical trials (n=169). Baseline prostate-specific antigen level, age, and metastasis ranged from 2.0 to 17.0 ng/ml, 43 to 75 yr, and one to seven lesions, respectively. Nodal, bone, nodal and bone, and visceral metastases were present in 49.7% (84/169), 33.7% (57/169), 15.9% (27/169), and 0.5% (1/169) of patients, respectively. Diagnostic conventional imaging was used in 43.7% (74/169) and positron emission tomography/computerised tomography in 56.2% (95/169) of patients. SABR and surgical metastasectomy with SABR were used in 78.3% (94/120) and 21.6% (26/120) of patients, respectively. Early progression-free survival ranged from 19% to 60%. Local control was reported as 93-100%. Grade II and III SABR toxicities were reported in 8% (8/100) and 1% (1/100) of patients, respectively. Grade IIIa and IIIb surgical complications were reported in 7.69% (2/26) and 0% (0/26) of patients, respectively. CONCLUSIONS: MDT is a promising experimental therapeutic approach in men with hormone-sensitive oligometastatic prostate cancer. Randomised comparative studies are required to ascertain its role and optimal timing in oligometastatic recurrence and efficacy in de novo synchronous disease. PATIENT SUMMARY: We looked at the evidence regarding the use of surgery or radiotherapy at target areas of cancer spread in men with newly diagnosed or relapsed advanced (metastatic) prostate cancer. Evidence supports both treatment options as promising approaches, but further large trials are required.
CONTEXT: Metastasis-directed therapy (MDT) in the form of stereotactic ablative radiation therapy (SABR), or in combination with surgical metastasectomy, may have a role in cancer control and disease progression. OBJECTIVE: To perform a systematic review of MDT (surgery or SABR) for oligometastatic (up to 10 metastases, recurrent or de novo) hormone-sensitive prostate cancer in addition to or following primary prostate gland treatment. EVIDENCE ACQUISITION: Medline, Embase, Cochrane Review Database, and clinical trial Databases were systematically searched for clinical trials reporting oncological outcomes and safety. The risk of bias was assessed with the Cochrane 2.0 or ROBINS-I tool. EVIDENCE SYNTHESIS: From 1025 articles identified, four clinical trials met the prespecified criteria. These included two randomised and two nonrandomised clinical trials (n=169). Baseline prostate-specific antigen level, age, and metastasis ranged from 2.0 to 17.0 ng/ml, 43 to 75 yr, and one to seven lesions, respectively. Nodal, bone, nodal and bone, and visceral metastases were present in 49.7% (84/169), 33.7% (57/169), 15.9% (27/169), and 0.5% (1/169) of patients, respectively. Diagnostic conventional imaging was used in 43.7% (74/169) and positron emission tomography/computerised tomography in 56.2% (95/169) of patients. SABR and surgical metastasectomy with SABR were used in 78.3% (94/120) and 21.6% (26/120) of patients, respectively. Early progression-free survival ranged from 19% to 60%. Local control was reported as 93-100%. Grade II and III SABRtoxicities were reported in 8% (8/100) and 1% (1/100) of patients, respectively. Grade IIIa and IIIb surgical complications were reported in 7.69% (2/26) and 0% (0/26) of patients, respectively. CONCLUSIONS: MDT is a promising experimental therapeutic approach in men with hormone-sensitive oligometastatic prostate cancer. Randomised comparative studies are required to ascertain its role and optimal timing in oligometastatic recurrence and efficacy in de novo synchronous disease. PATIENT SUMMARY: We looked at the evidence regarding the use of surgery or radiotherapy at target areas of cancer spread in men with newly diagnosed or relapsed advanced (metastatic) prostate cancer. Evidence supports both treatment options as promising approaches, but further large trials are required.
Authors: Palanivel Velmurugan; Vinayagam Mohanavel; Anupama Shrestha; Subpiramaniyam Sivakumar; Atif Abdulwahab A Oyouni; Osama M Al-Amer; Othman R Alzahrani; Mohammed I Alasseiri; Abdullah Hamadi; Adel Ibrahim Alalawy Journal: Biomed Res Int Date: 2022-06-10 Impact factor: 3.246
Authors: Martin J Connor; Mesfin G Genie; David Burns; Edward J Bass; Michael Gonzalez; Naveed Sarwar; Alison Falconer; Stephen Mangar; Tim Dudderidge; Vincent Khoo; Mathias Winkler; Hashim U Ahmed; Verity Watson Journal: Eur Urol Open Sci Date: 2021-12-20
Authors: Martin John Connor; Mesfin G Genie; Michael Gonzalez; Naveed Sarwar; Kamalram Thippu Jayaprakash; Gail Horan; Feargus Hosking-Jervis; Natalia Klimowska-Nassar; Johanna Sukumar; Tzveta Pokrovska; Dolan Basak; Angus Robinson; Mark Beresford; Bhavan Rai; Stephen Mangar; Vincent Khoo; Tim Dudderidge; Alison Falconer; Mathias Winkler; Verity Watson; Hashim Uddin Ahmed Journal: BMJ Open Date: 2021-11-18 Impact factor: 2.692